Icro Meattini1, Nadia Pasinetti2, Bruno Meduri3, Fiorenza De Rose4, Maria Carmen De Santis5, Pierfrancesco Franco6, Valentina Lancellotta7, Francesca Rossi8, Calogero Saieva9, Isacco Desideri10, Camilla Delli Paoli11, Elisa D'Angelo12, Luca Triggiani13, Paolo Bastiani8, Filippo Alongi14, Laura Lozza15, Cynthia Aristei16, Umberto Ricardi17, Marta Scorsetti18, Lorenzo Livi11. 1. Azienda Ospedaliero Universitaria Careggi - University of Florence, Radiation Oncology Unit, Florence, Italy; Clinical Oncology Breast Cancer Group (COBCG), Italy. Electronic address: icro.meattini@unifi.it. 2. Radiation Oncology Department, Brescia University and Spedali Civili, Brescia, Italy; Clinical Oncology Breast Cancer Group (COBCG), Italy. 3. University Hospital of Modena, Radiation Oncology Unit, Italy; Clinical Oncology Breast Cancer Group (COBCG), Italy. 4. Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research Hospital, Rozzano, Italy; Clinical Oncology Breast Cancer Group (COBCG), Italy. 5. National Cancer Institute of Milan, Italy; Clinical Oncology Breast Cancer Group (COBCG), Italy. 6. University of Turin, Department of Oncology - Radiation Oncology, Italy; Clinical Oncology Breast Cancer Group (COBCG), Italy. 7. University of Perugia and Perugia General Hospital, Radiation Oncology Section, Italy; Clinical Oncology Breast Cancer Group (COBCG), Italy. 8. Azienda USL Toscana Centro, Radiotherapy Unit, Florence, Italy. 9. Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy. 10. Azienda Ospedaliero Universitaria Careggi - University of Florence, Radiation Oncology Unit, Florence, Italy; Clinical Oncology Breast Cancer Group (COBCG), Italy. 11. Azienda Ospedaliero Universitaria Careggi - University of Florence, Radiation Oncology Unit, Florence, Italy. 12. University Hospital of Modena, Radiation Oncology Unit, Italy. 13. Radiation Oncology Department, Brescia University and Spedali Civili, Brescia, Italy. 14. Sacro Cuore Don Calabria Hospital, Verona, Italy; University of Brescia, Italy. 15. National Cancer Institute of Milan, Italy. 16. University of Perugia and Perugia General Hospital, Radiation Oncology Section, Italy. 17. University of Turin, Department of Oncology - Radiation Oncology, Italy. 18. Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research Hospital, Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, Italy.
Abstract
BACKGROUND AND PURPOSE: Breast-conserving surgery (BCS) and whole breast radiation (RT) with or without endocrine therapy (ET) represent the standard of care for ductal carcinoma in situ (DCIS). The use of adjuvant treatments after surgery is still controversial in this setting. We performed a retrospective multicenter analysis on a series of DCIS patients treated with BCS and adjuvant RT. MATERIALS AND METHODS: We collected clinical data from nine Italian centers on 1072 women having a diagnosis of DCIS and treated between 1997 and 2012. We reported on the 5- and 10-year local recurrence (LR) rates, overall survival, and breast cancer specific survival (BCSS) employing the Kaplan-Meier method. RESULTS: At a median follow-up of 8.4 years, 67 LR (6.3%) and 47 deaths (4.4%) were observed. LR rates at 5 and 10 years were 3.4% and 7.6%, respectively. BCSS rates at 5 and 10 years were 99.7% and 99.1%, respectively. At univariate regression analysis, postmenopausal state (p = 0.009), estrogen receptor (ER) (p = 0.0001) and progesterone receptor (p = 0.018) positivity and ET (p = 0.006) were inversely correlated with LR. Final surgical margins (FSM) status <1 mm was significantly correlated with higher LR (p = 0.003). At multivariate regression analysis postmenopausal state (p = 0.03), and ER positive (p = 0.045) maintained the significant favorable feature, while FSM <1 mm (p = 0.024) confirmed its negative impact on LR. CONCLUSIONS: Our real-life study pointed out the significant favorable prognostic role of postmenopausal state and ER positive status on LR occurrence. FSM <1 mm was significantly correlated to a higher chance to experience LR.
BACKGROUND AND PURPOSE: Breast-conserving surgery (BCS) and whole breast radiation (RT) with or without endocrine therapy (ET) represent the standard of care for ductal carcinoma in situ (DCIS). The use of adjuvant treatments after surgery is still controversial in this setting. We performed a retrospective multicenter analysis on a series of DCISpatients treated with BCS and adjuvant RT. MATERIALS AND METHODS: We collected clinical data from nine Italian centers on 1072 women having a diagnosis of DCIS and treated between 1997 and 2012. We reported on the 5- and 10-year local recurrence (LR) rates, overall survival, and breast cancer specific survival (BCSS) employing the Kaplan-Meier method. RESULTS: At a median follow-up of 8.4 years, 67 LR (6.3%) and 47 deaths (4.4%) were observed. LR rates at 5 and 10 years were 3.4% and 7.6%, respectively. BCSS rates at 5 and 10 years were 99.7% and 99.1%, respectively. At univariate regression analysis, postmenopausal state (p = 0.009), estrogen receptor (ER) (p = 0.0001) and progesterone receptor (p = 0.018) positivity and ET (p = 0.006) were inversely correlated with LR. Final surgical margins (FSM) status <1 mm was significantly correlated with higher LR (p = 0.003). At multivariate regression analysis postmenopausal state (p = 0.03), and ER positive (p = 0.045) maintained the significant favorable feature, while FSM <1 mm (p = 0.024) confirmed its negative impact on LR. CONCLUSIONS: Our real-life study pointed out the significant favorable prognostic role of postmenopausal state and ER positive status on LR occurrence. FSM <1 mm was significantly correlated to a higher chance to experience LR.
Authors: Icro Meattini; Marta Scorsetti; Fiorenza De Rose; Maria Carmen De Santis; Bruno Meduri; Ciro Franzese; Davide Franceschini; Pierfrancesco Franco; Nadia Pasinetti; Valentina Lancellotta; Patrizia Giacobazzi; Eliana La Rocca; Elisa D'Angelo; Laura Lozza; Lorenzo Livi Journal: J Cancer Res Clin Oncol Date: 2021-01-02 Impact factor: 4.553
Authors: Charles E Leonard; Shannon P Tole; Michelle P Turner; John P Bennett; Kathryn T Howell; Dennis L Carter Journal: Front Oncol Date: 2021-06-17 Impact factor: 6.244
Authors: Michael H Tomasson; Mahmoud Ali; Vanessa De Oliveira; Qian Xiao; Yogesh Jethava; Fenghuang Zhan; Adam M Fitzsimmons; Melissa L Bates Journal: Int J Mol Sci Date: 2018-11-16 Impact factor: 5.923